Allergy Shots for Kids: PAT Study, Age Threshold, and At-Home SCIT
Allergy shots are appropriate for children generally 5 years old and up — and 3 years of pediatric SCIT cuts the later development of asthma roughly in half per the PAT study (Jacobsen 2007, OR 4.6, 95% CI 1.5–13.7). The ≥5 yr threshold is based on cooperation and symptom-reporting ability, not a hard chronological rule per Cox 2011 PP3. This disease-modifying asthma-prevention benefit is unique to pediatric SCIT — adults do not gain the same prevention finding.
6 peer-reviewed sources
Allergy shots are safe for children typically from age 5, with no strict lower age limit per Cox 2011 PP3. Three years of pediatric pollen SCIT roughly halves the later development of asthma at 10-year follow-up, per the PAT study (Jacobsen 2007, OR 4.6).
The essentials
Allergy shots are appropriate for children generally 5 years old — and 3 years of pediatric SCIT cuts the later development of asthma roughly in half per the PAT study (Jacobsen 2007, OR 4.6). The AAAAI/ACAAI/JCAAI Practice Parameter Third Update (Cox L et al., JACI 2011;127(1 Suppl):S1–S55; DOI 10.1016/j.jaci.2010.09.034) Summary Statements 17 and 18 explicitly state there is no specific lower age limit for immunotherapy if indications are present. The ≥5 yr convention is based on the developmental ability to cooperate with injections and report early systemic-reaction symptoms such as throat tightness or chest tightness — not a hard chronological cutoff.
Before committing a child to a 3–5 year SCIT course, Curex's at-home IgE testing with board-certified allergist review confirms whether a child is monosensitized (the PAT-study profile most likely to benefit from asthma prevention) or polysensitized (multi-allergen SCIT territory), which directs the treatment decision.
The central content asset of pediatric SCIT — distinguishing it clinically from adult SCIT — is the **PAT study (Preventive Allergy Treatment)** asthma-prevention finding. The PAT study enrolled 205 children aged 6–14 (mean 10.7 yr) with grass and/or birch pollen allergy but no other clinically important sensitization, randomized to 3 years of pollen SCIT versus no SCIT. Initial findings (Möller C et al., JACI 2002;109:251–256; DOI 10.1067/mai.2002.121317): actively treated children had significantly fewer asthma diagnoses at 3 years (OR 2.52, P<.05) and improved methacholine bronchial provocation. Five-year follow-up (Niggemann B et al., Allergy 2006;61:855–859): preventive effect persisted 2 years after stopping (OR 2.68, 95% CI 1.3–5.7). Ten-year follow-up (Jacobsen L et al., Allergy 2007;62:943–948; DOI 10.1111/j.1398-9995.2007.01451.x): asthma developed in 24/53 controls vs 16/64 SCIT patients; the longitudinal OR for remaining asthma-free was **4.6 (95% CI 1.5–13.7)** favoring SCIT. This is the basis for the statement that 3-year pediatric pollen SCIT roughly halves later asthma incidence.
Pediatric SCIT uses the same FDA-licensed standardized extracts and the same therapeutic maintenance doses as adult SCIT — weight-based dosing is NOT standard practice in children. The target is an effective maintenance dose of major allergen (the same microgram-level targets used in adults). Pediatric compliance is parent-mediated and typically better than adult self-directed adherence; Tkacz JP et al. (Curr Med Res Opin 2021) found 23.9% of adults never returned after the first injection, while parent oversight generally closes this gap in pediatric SCIT.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
The distinguishing efficacy of pediatric SCIT is disease modification — asthma prevention — not merely symptom relief. The PAT study 10-year follow-up (Jacobsen L et al., Allergy 2007) documented a longitudinal OR of 4.6 (95% CI 1.5–13.7) for remaining asthma-free in the SCIT group versus untreated controls. For symptom and medication outcomes, Cochrane meta-analysis (Calderón MA et al., 2007; 51 RCTs, 2,871 patients) found SMD −0.73 for symptom scores and SMD −0.57 for medication use — these broad meta-analytic results span pediatric and adult populations.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youSide effects — what to watch for
Pediatric SCIT safety is comparable to adult SCIT per Epstein TG et al. (Ann Allergy Asthma Immunol 2013/2014; PMID 23535092/24607043), with some evidence of fewer systemic reactions in children. The 30-minute post-injection observation period is required after every injection regardless of age. Parents should be prepared to recognize the difference between normal local reactions (arm swelling, redness) and systemic symptoms requiring emergency care.
Frequently asked questions
What age can kids start allergy shots?
There is no specific lower age limit for allergy shots per the AAAAI/ACAAI Practice Parameter Third Update (Cox et al., JACI 2011). In practice, most allergists begin SCIT at age 5 or older, because younger children may not reliably cooperate with the injection technique or communicate early systemic-reaction symptoms such as throat tightness, hoarseness, or chest tightness. The limiting factor is developmental cooperation and symptom-reporting ability, not a hard chronological cutoff. Some practices begin earlier for children with severe allergic asthma and clear monosensitization where the benefit-risk calculation is compelling.
What is the PAT study and why does it matter for pediatric allergy shots?
The PAT (Preventive Allergy Treatment) study is the pivotal RCT establishing that allergy shots in childhood can prevent the development of asthma. The trial enrolled 205 children aged 6–14 with grass or birch pollen allergy and no other clinically important sensitization, randomizing them to 3 years of pollen SCIT versus no SCIT. At 10-year follow-up (Jacobsen L et al., Allergy 2007;62:943–948), asthma had developed in 24 of 53 controls versus only 16 of 64 SCIT-treated children. The longitudinal odds ratio for remaining asthma-free was 4.6 (95% CI 1.5–13.7) favoring SCIT. The finding is clinically important because it shows that allergy shots do more than relieve symptoms — in the right pediatric population (monosensitized pollen-allergic children with rhinitis), they may prevent asthma entirely.
Are allergy shots dosed differently for children versus adults?
No — pediatric SCIT uses the same FDA-licensed allergen extracts and the same therapeutic maintenance doses as adult SCIT. Weight-based dosing is NOT standard practice in children. The target is the same effective maintenance dose of major allergen that is used in adult protocols (e.g., the same BAU or microgram targets for standardized cat, grass, or dust mite extracts). Children receive the same standardized dilution ladder — starting from the most dilute vial and advancing weekly — as adults. The clinical difference is in cooperation and observation protocols, not in extract composition or dosing targets.
How safe are allergy shots for children?
Pediatric SCIT safety is comparable to adult SCIT per AAAAI/ACAAI surveillance (Epstein TG et al., Ann Allergy Asthma Immunol 2013/2014; PMID 23535092/24607043). The population-wide fatality rate across both ages is approximately 1 per 23.3 million injection visits. Some surveillance data suggests children may have a slightly lower systemic reaction rate than adults, though this finding is not conclusive. All children receiving SCIT must observe the 30-minute post-injection observation period required by Cox 2011 PP3, and the clinic must be equipped with epinephrine, oxygen, and emergency-response capacity.
Can children take sublingual allergy tablets instead of shots?
Yes. Four FDA-approved sublingual immunotherapy (SLIT) tablets have pediatric-labeled indications: Grastek (Timothy grass, ALK; ages 5–65 yr), Ragwitek (short ragweed, ALK; ages 5–65 yr), Oralair (5-grass mix, Stallergenes Greer; ages 5–65 yr in the current US label, with dose titration required for ages 5–17), and Odactra (house dust mite, ALK; ages 5–65 yr after the 2025 label revision). All four carry boxed warnings for anaphylaxis, require a supervised first dose under physician observation, and require co-prescription of epinephrine. None cover multi-allergen polysensitized patients — for children sensitized to multiple allergens simultaneously, compounded SCIT remains the standard approach. For families who prefer SCIT's disease-modifying mechanism but want to avoid weekly clinic trips, Curex provides at-home SCIT for eligible pediatric patients at $129/month, with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand.
Will my child need allergy shots for life?
No. The standard SCIT course for children is 3–5 years, not a lifelong commitment. The PAT study (Jacobsen L et al., Allergy 2007) documented that the asthma-prevention benefit persisted for at least 10 years after the 3-year SCIT course ended — without ongoing injections. The long-term disease-modifying effect means that completing the full 3-year minimum course confers benefit that persists after discontinuation. Cox 2011 PP3 does not recommend indefinite SCIT; duration beyond 5 years is considered case-by-case based on allergen severity and patient response. If a child completes the full course and remains symptom-free, they should not need to restart.
What should parents watch for after their child's allergy shot?
After a child's allergy shot, parents should watch for two categories of reactions during the mandatory 30-minute clinic observation and in the hours at home. Normal local reactions include arm swelling, redness, or itching at the injection site — these are common (roughly two-thirds of injections per the LOCAL study, Calabria CW et al., Ann Allergy Asthma Immunol 2009). Reactions larger than 5 cm or lasting beyond 48 hours should be reported to the allergist. Emergency symptoms requiring 911 and immediate epinephrine use include: throat tightness, voice change, hoarseness, difficulty breathing, generalized hives, wheeze, lightheadedness, or abdominal cramping starting outside the arm. If your child reports any of these at home after leaving the clinic, call 911 — do not wait.
Related Articles
Allergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Injection: One Visit Explained | Curex
An allergy injection is one step in a 3-to-5-year SCIT course. Learn pre-injection screening, technique, the 30-min observation, and why singular search intent often finds depot steroids instead.
Read moreCat Allergy Shots for Humans | Curex SCIT Guide
Cat allergy shots use FDA-standardized Fel d 1 extract for ~72% symptom relief. RCT evidence, schedule, plus at-home SCIT from Curex at $129/mo.
Read moreAllergy Shot for Kids: First Injection Parent Guide | Curex
First allergy shot: multi-year SCIT from age 5 (Cox 2011 PP3). Local vs systemic reactions, PAT asthma-prevention, at-home SCIT option.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.